Mitsubishi Tanabe Pharma (MTPA) Collaborates with Massachusetts General Hospital (MGH) for ALS Biomarker Study

 Mitsubishi Tanabe Pharma (MTPA) Collaborates with Massachusetts General Hospital (MGH) for ALS Biomarker Study

Mitsubishi Tanabe Pharma (MTPA) Collaborates with Massachusetts General Hospital (MGH) for ALS Biomarker Study

Shots:

  • Mitsubishi Tanabe Pharma (MTPA) enters into a collaboration with Massachusetts General Hospital (MGH) Neurological Clinical Research Institute (NCRI) to conduct ALS biomarker study for identification of biomarkers in patients with amyotrophic lateral sclerosis (ALS)
  • The ALS biomarker study will evaluate 4 biomarkers enrolling 200 patients receiving Radicava (edaravone) for 24wks. across 40 sites and will be conducted & sponsored by MGH & MTPA respectively with its expected interim analyses in H2’19
  • RADICAVA (edaravone, IV) is a neuroprotective agent indicated for the treatment of ALS and has received approval in the US, Japan and South Korea in May’17, Jun’15 & Dec’15 respectively for ALS

Click here to read full press release/ article | Ref: Mitsubishi Tanabe Pharma | Image: MGH

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post